EIK 1003
Alternative Names: EIK-1003; IMP-1734Latest Information Update: 16 Jan 2024
At a glance
- Originator IMPACT Therapeutics
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 11 Dec 2023 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06253130)
- 07 Jun 2023 IMPACT Therapeutics plans a phase I trial for Cancer in 2023
- 01 Jun 2023 Eikon and Impact plans to file a IND application for IMP 1734 by the end of the third quarter of 2023.